PharmaTher Holdings Ltd.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PHRM.CN research report →
Companywww.pharmather.com
PharmaTher Holdings Ltd. , a clinical-stage psychedelics biotech company, focuses on the research, development, and commercialization of novel uses, formulations, and delivery methods of psychedelics to treat mental illness, neurological, and pain disorders. The company's product in pipeline includes Ketamine intravenous injection, which is in Phase II and III clinical trials for Parkinson's disease, anesthesia and sedation, and amyotrophic lateral sclerosis indications.
- CEO
- Fabio Chianelli
- IPO
- 2021
- HQ
- Toronto, ON, CA
Price Chart
Valuation
- Market Cap
- $5.92M
- P/E
- -5.38
- P/S
- 0.00
- P/B
- 11.09
- EV/EBITDA
- -3.61
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -155.46%
- ROIC
- -241.01%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-1,526,106 · 51.01%
- EPS
- $-0.02 · 51.27%
- Op Income
- $-1,523,637
- FCF YoY
- 65.64%
Performance & Tape
- 52W High
- $0.77
- 52W Low
- $0.06
- 50D MA
- $0.08
- 200D MA
- $0.16
- Beta
- 2.76
- Avg Volume
- 151.90K
Get TickerSpark's AI analysis on PHRM.CN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our PHRM.CN Coverage
We haven't published any research on PHRM.CN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate PHRM.CN Report →